李氏大藥廠(00950.HK)中期純利大增1.5倍,中期息0.027港元
格隆匯 8 月 27日丨李氏大藥廠(00950.HK)公佈,截至2020年6月30日止6個月,公司實現收益5.57億港元,同比減少8.4%;毛利3.66億港元,同比減少9.1%;公司擁有人應占溢利9698.2萬港元,同比增長153.3%;基本每股盈利16.49港仙,擬派中期息每股0.027港元。
於回顧期內,原訂於2021年12月3日屆1滿的《再寧平》®產品特許在得到補償下提早終止。鑑於在中國已有多種樂卡地平的仿製藥可供選擇,集團相信於此時提早終止此產品不僅帶來短期財務禆益,更開拓空間讓本集團於不久將來推出仿製版本,長遠促進業務蓬勃發展。集團已就此確認4120.8萬港元的一次性補償收入。此外,去年同期集團旗下擁有65%權益的附屬公司中國腫瘤醫療有限公司產生非經常性虧損約1.09億港元,有關虧損乃因終止用於治療晚期肝癌的Pexa-Vec第III期臨牀試驗後的無形資產減值而產生,而回顧期內則並無錄得大額無形資產減值。
公告稱,繼第一季度COVID-19大流行導致集團的新藥研究及開發活動放緩後,第二季度的研發活動逐步恢復,而2020年上半年的研發活動開支為1.51億港元,相當於回顧期內收益的27.1%。其中,7516萬港元已確認為費用,而7597.6萬港元。
此外,鑑於COVID-19疫情在全球蔓延及對口罩的需求大幅飆升,集團的聯營公司普樂藥業有限公司目前正於其符合ISO-8100,000級要求的無塵車間運行兩台全自動化口罩生產機。截至目前為止,口罩生產量已提升至每日約40,000個,透過vmask.com.hk在網上銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.